Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUBITO: Personalized therapy for high-risk BRCA1-like stage III breast cancer
2024-516196-32-00Phase 3Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of olaparib in breast cancer (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Overall survival (all patients). Planned start Jan 2025; status: authorised.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-516196-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516196-32-00.